Prenatal diagnosis of myopathy, encephalopathy, lactic acidosis, and stroke-like syndrome: contribution to understanding mitochondrial DNA segregation during human embryofetal development
- C Bouchet1,
- J Steffann1,4,
- J Corcos3,
- S Monnot1,2,
- V Paquis2,
- A Rötig1,4,
- S Lebon1,
- P Levy1,
- G Royer1,
- I Giurgea1,
- N Gigarel1,
- A Benachi3,
- Y Dumez3,
- A Munnich1,4,
- J P Bonnefont1,4
- 1Department of Genetics, Hôpital Necker-Enfants Malades, Paris, France
- 2Department of Genetics, Hôpital Archet 2, Nice
- 3Department of Obstetrics, Hôpital Necker-Enfants Malades, Paris
- 4Unité INSERMU781, Paris
- Correspondence to: J P Bonnefont Unité INSERMU781, Paris 75015, France;bonnefon{at}necker.fr
- Received 28 April 2005
- Accepted 16 April 2006
- Revised 15 April 2006
- Published Online First 11 May 2006
Abstract
Introduction: Myopathy, encephalopathy, lactic acidosis, and stroke-like (MELAS) syndrome, a maternally inherited disorder that is among the most common mitochondrial DNA (mtDNA) diseases, is usually associated with the m.3242A>G mutation of the mitochondrial tRNAleu gene. Very few data are available with respect to prenatal diagnosis of this serious disease. The rate of mutant versus wild-type mtDNA (heteroplasmy) in fetal DNA is indeed considered to be a poor indicator of postnatal outcome.
Materials and methods: Taking advantage of a novel semi-quantitative polymerase chain reaction test for m.3243A>G mutant load assessment, we carried out nine prenatal diagnoses in five unrelated women, using two different fetal tissues (chorionic villi v amniocytes) sampled at two or three different stages of pregnancy.
Results: Two of the five women, although not carrying m.3243A>G in blood or extra-blood tissues, were, however, considered at risk for transmission of the mutation, as they were closely related to MELAS-affected individuals. The absence of 3243A>G in the blood of first degree relatives was associated with no mutated mtDNA in the cardiovascular system (CVS) or amniocytes, and their three children are healthy, with a follow-up of 3 months–3 years. Among the six fetuses from the three carrier women, three were shown to be homoplasmic (0% mutant load), the remaining three being heteroplasmic, with a mutant load ranging from 23% to 63%. The fetal mutant load was fairly stable at two or three different stages of pregnancy in CVS and amniocytes. Although pregnancy was terminated in the case of the fetus with a 63% mutant load, all other children are healthy with a follow-up of 3 months–6 years.
Conclusion: These data suggest that a prenatal diagnosis for MELAS syndrome might be helpful for at-risk families.
- CVS, chorionic villous sampling
- MELAS, myopathy, encephalopathy, lactic acidosis, and stroke-like
- mtDNA, mitochondrial DNA
- PCR, polymerase chain reaction
Footnotes
-
Published Online First 11 May 2006
-
Competing interests: None declared.









